@hirotsugukitayama.bsky.social
Reposted
Although use of RAAS inhibitors is contraindicated in the 2nd & 3rd trimesters of pregnancy, a relevant number of pregnancies are still exposed. Read this Original Article on postnatal & long-term outcomes after in utero exposure to RAAS-I. Open Access
link.springer.com/article/10.1...
link.springer.com/article/10.1...
December 31, 2025 at 6:38 PM
Although use of RAAS inhibitors is contraindicated in the 2nd & 3rd trimesters of pregnancy, a relevant number of pregnancies are still exposed. Read this Original Article on postnatal & long-term outcomes after in utero exposure to RAAS-I. Open Access
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted
Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles
#nephrology #nephsky
link.springer.com/article/10.1...
#nephrology #nephsky
link.springer.com/article/10.1...
Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles - Pediatric Nephrology
Background Rituximab is considered a therapeutic option in children with refractory nephrotic syndrome (RNS). However, the efficacy and safety of rituximab treatment remain unclear. Objective This stu...
link.springer.com
November 8, 2025 at 2:48 PM
Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles
#nephrology #nephsky
link.springer.com/article/10.1...
#nephrology #nephsky
link.springer.com/article/10.1...
